The FDA slammed ExThera with a warning letter for deviating from the regulatory agency’s guidelines by promoting and selling its Seraph 100 blood filter device to treat cancer patients under specious conditions.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
The FDA slammed ExThera with a warning letter for deviating from the regulatory agency’s guidelines by promoting and selling its Seraph 100 blood filter device to treat cancer patients under specious conditions.